The endocannabinoid system plays a key role in nicotine addiction and could be targeted for smoking cessation
The CB1 receptor antagonist rimonabant helped smokers quit in clinical trials, and newer approaches targeting other endocannabinoid components may provide similar benefits without psychiatric side effects.
Quick Facts
What This Study Found
This review compiled evidence for the endocannabinoid system's involvement in nicotine addiction. The CB1 receptor inverse agonist rimonabant reduced nicotine-taking and nicotine-seeking in animal studies and improved smoking quit rates in randomized clinical trials.
However, rimonabant was removed from the market due to increased psychiatric side effects (depression, suicidality) in humans. This withdrawal prompted research into alternative ways to modulate the endocannabinoid system for smoking cessation.
The review highlighted newer approaches targeting FAAH (the enzyme that breaks down anandamide), MAGL (the enzyme that breaks down 2-AG), and other endocannabinoid system components. These approaches might modulate nicotine addiction pathways without the psychiatric risks associated with directly blocking CB1 receptors.
Key Numbers
Rimonabant improved quit rates in clinical trials. Removed from market due to psychiatric side effects. Multiple alternative endocannabinoid targets identified: FAAH, MAGL, and other components.
How They Did This
Narrative review of preclinical and clinical evidence for the endocannabinoid system's role in nicotine addiction, covering CB1 receptor antagonism, enzyme inhibition, and other modulatory approaches.
Why This Research Matters
Smoking remains a leading cause of preventable death, and existing cessation medications have limited effectiveness. If endocannabinoid system modulation can help people quit smoking without the psychiatric risks of rimonabant, it could save many lives.
The Bigger Picture
The rimonabant story illustrates both the promise and the pitfalls of cannabinoid-based medicine. The system is clearly involved in addiction, but blocking it too broadly causes serious problems. More targeted approaches are needed.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Many alternative approaches are still preclinical. The transition from animal models to human clinical applications has proven difficult for endocannabinoid-based treatments.
Questions This Raises
- ?Which endocannabinoid targets offer the best balance of efficacy and safety for smoking cessation?
- ?Could FAAH inhibitors help smokers quit without psychiatric side effects?
- ?Would these approaches work for cannabis dependence as well?
Trust & Context
- Key Stat:
- Rimonabant helped smokers quit but was withdrawn due to side effects
- Evidence Grade:
- Narrative review combining clinical trial evidence (rimonabant) with preclinical data on alternative approaches.
- Study Age:
- Published in 2015. Endocannabinoid-based smoking cessation research has continued.
- Original Title:
- Role of the endogenous cannabinoid system in nicotine addiction: novel insights.
- Published In:
- Frontiers in psychiatry, 6, 41 (2015)
- Authors:
- Gamaleddin, Islam Hany, Trigo, Jose M(6), Gueye, Aliou B, Zvonok, Alexander, Makriyannis, Alexandros, Goldberg, Steven R, Le Foll, Bernard
- Database ID:
- RTHC-00963
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabinoid drugs help you quit smoking?
One cannabinoid drug (rimonabant) improved smoking cessation rates in clinical trials but was pulled from the market due to psychiatric side effects. Researchers are now exploring safer alternatives that target different parts of the endocannabinoid system.
Why does the endocannabinoid system affect nicotine addiction?
The endocannabinoid system interacts with dopamine reward pathways that nicotine hijacks. Modulating this system can reduce the rewarding effects of nicotine and decrease drug-seeking behavior, at least in animal models.
Read More on RethinkTHC
- 30-days-without-weed
- 420-sober-survival-guide
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- CBT-cannabis-recovery
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-relapse-cycle-pattern
- cannabis-use-disorder-test
- cold-turkey-vs-taper-quit-weed
- creativity-without-weed-quitting-artist-musician
- cross-addiction-quit-weed-start-drinking
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- hobbies-after-quitting-weed
- how-to-quit-weed
- identity-after-quitting-weed
- is-weed-addictive
- is-weed-addictive-science
- journaling-weed-withdrawal
- leaving-stoner-culture-identity
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-and-alcohol
- quitting-weed-creativity
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-face-changes-skin
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- quitting-weed-weight-loss-gain
- rehab-for-weed-addiction-necessary
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- should-i-quit-weed
- signs-of-cannabis-use-disorder
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-00963APA
Gamaleddin, Islam Hany; Trigo, Jose M; Gueye, Aliou B; Zvonok, Alexander; Makriyannis, Alexandros; Goldberg, Steven R; Le Foll, Bernard. (2015). Role of the endogenous cannabinoid system in nicotine addiction: novel insights.. Frontiers in psychiatry, 6, 41. https://doi.org/10.3389/fpsyt.2015.00041
MLA
Gamaleddin, Islam Hany, et al. "Role of the endogenous cannabinoid system in nicotine addiction: novel insights.." Frontiers in psychiatry, 2015. https://doi.org/10.3389/fpsyt.2015.00041
RethinkTHC
RethinkTHC Research Database. "Role of the endogenous cannabinoid system in nicotine addict..." RTHC-00963. Retrieved from https://rethinkthc.com/research/gamaleddin-2015-role-of-the-endogenous
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.